EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort

Tabitha Arn-Roth, Tessa Bernasconi, Bettina Sarah Frauchiger, Insa Korten, Carmen Casaulta, Elisabeth Kieninger, Philipp Latzin

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2025.12.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Tabitha Arn-Roth und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Fre…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has transformed cystic fibrosis (CF) therapy, yet observational clinical data in children with preserved spirometry remain limited. The lung clearance index (LCI) is used to monitor treatment response, but exhibits considerable short-term variability, affecting the interpretation of two-point comparisons. METHODS: We retrospectively analysed longitudinal clinical data from a typical pediatric CF cohort. Multiple measurements per patient within 12 months before and after ETI initiation enabled LCI variability assessment and comparison of mean LCI before and under treatment. We assessed the LCI response to ETI, its association with baseline LCI, FEV₁ z-score, sweat chloride, genotype, and changes in within-patient LCI variability. RESULTS: Mean LCI in 59 patients (median age 11.6y) decreased from 7.9 (IQR 6.9-9.4) to 6.4 (6.1-7.0) (p 10. CONCLUSIONS: ETI reduces ventilation inhomogeneity in children with CF, the magnitude of LCI reduction is strongly dependent on baseline disease severity. Within-patient LCI variability is reduced, indicating greater disease stability. LCI is a sensitive marker, improvements upon ETI treatment are well predictable particularly in early disease stages, observational data support its routine use in clinical monitoring of pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesBenzodioxolesHumansMaleRetrospective StudiesFemaleChildAdolescentCystic Fibrosis Transmembrane Conductance RegulatorRespiratory Function TestsTreatment OutcomeSpirometry

Stichwörter der Autor:innen

CFTR modulatorsCystic fibrosisElexacaftor/tezacaftor/ivacaftor (ETI)Lung clearance index (LCI)Pediatric pulmonologyReal-world data

Substanzen

AminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxoles

Autor:innen und Institutionen

  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: tabitha.arn-ro…
  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: tessa.bernasco…
  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: bettina.frauch…
  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: insa.korten@in…
  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: carmen.casault…
  • Division of Pediatric Respiratory Medicine and Allergology, Departement of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, Bern, Switzerland. Electronic address: elisabeth.kien…

Förderung

  • Vertex Pharmaceuticals Incorporated
  • Swiss National Science Foundation

Zitieren

APA

Arn-Roth, T., Bernasconi, T., Frauchiger, B. S., Korten, I., Casaulta, C., Kieninger, E., & Latzin, P. (2026). Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.12.016

Vancouver

Arn-Roth T, Bernasconi T, Frauchiger BS, Korten I, Casaulta C, Kieninger E, et al. Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.12.016

BibTeX
@article{ArnRoth2026,
  author = {Arn-Roth, Tabitha and Bernasconi, Tessa and Frauchiger, Bettina Sarah and Korten, Insa and Casaulta, Carmen and Kieninger, Elisabeth and Latzin, Philipp},
  title = {Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2025.12.016}
}
Kostenlos starten →